Core Viewpoint - The public fund industry in China is entering a phase of high-quality development, with ongoing reforms aimed at optimizing and upgrading the sector, focusing on product innovation, team-based research, and enhancing international competitiveness [1][6]. Group 1: Product Innovation - The public fund industry is currently adopting a dual-line strategy for product innovation, focusing on equity products and absolute return products like FOFs to meet diverse investor needs [2][3]. - In January, 123 new funds were established, with a total issuance scale of 1,202.11 billion yuan, of which 95 were equity funds with an issuance scale of 812.43 billion yuan [2]. - Notable equity funds include the Guangfa Research Smart Mixed Fund, which raised 72.21 billion yuan, marking the first fund to exceed 70 billion yuan since November 2022 [2]. - FOFs have also gained traction, with an issuance scale of 199.43 billion yuan in January, indicating strong demand for low-risk investment options [3]. Group 2: Research and Team Dynamics - The public fund industry is shifting towards a team-based research model, moving away from the traditional reliance on star fund managers, which is expected to optimize the industry ecosystem [4]. - The establishment of the Ruiyuan Research Balanced Three-Year Holding Mixed Fund, managed by a team of new faces rather than established managers, exemplifies this trend [4]. - Changes in fund management personnel are also evident, with new managers being appointed to replace seasoned professionals, indicating a generational shift in leadership [5]. Group 3: Long-term Investment Ecosystem - The China Securities Regulatory Commission emphasizes the need for ongoing reforms to broaden long-term funding sources and promote long-term, rational, and value-based investments [6]. - Analysts predict that by 2030, the scale of public funds could exceed 50 trillion yuan, driven by deeper financial asset allocation by residents and the influx of long-term capital [6]. - The industry is expected to see a shift towards passive investment strategies and ETFs, which will become essential tools for long-term allocation [6]. Group 4: International Expansion - Leading public funds are increasingly focusing on international expansion, with products like the Southern Dongying CSI A500 ETF being listed on international exchanges, enhancing access for global investors [7]. - Strategic partnerships, such as the collaboration between Huatai and Korean investment firms, are being formed to deepen engagement in the Hong Kong ETF market [7]. - The industry is committed to integrating technology and enhancing service offerings to support national development and capital market reforms [7].

Core Insights - The public fund industry in China is focusing on high-quality development and reform, as emphasized by the China Securities Regulatory Commission (CSRC) during the 2026 system work meeting [2][7] Product Innovation - The public fund sector is witnessing continuous product innovation, with a dual focus on equity products and absolute return products like FOFs [2][3] - In January, 123 new funds were established, with a total issuance scale of 120.21 billion yuan, of which 95 were equity funds totaling 81.24 billion yuan [2] - Active equity funds have shown a resurgence, with notable issuances such as the GF Research Smart Mixed Fund at 7.22 billion yuan, marking the first active equity fund to exceed 7 billion yuan since November 2022 [2][3] Investment Trends - The current investment direction aligns closely with market trends, including cloud computing ETFs, AI ETFs, and funds focused on consumer and digital economy themes [3] - FOFs have gained traction, with a total issuance of 19.94 billion yuan in January, and 14 products still in the issuance phase as of February 2 [3] Research and Team Dynamics - The public fund industry is shifting towards a team-based research model, moving away from the traditional star fund manager approach [5] - Newer fund managers are emerging, as seen in the establishment of the Ruiyuan Research Balanced Fund, which was managed by a team of less-known managers rather than established stars [5][6] Long-term Investment Ecosystem - The CSRC aims to deepen reforms in the public fund sector, focusing on long-term investment strategies and risk management tools to foster a "long money, long investment" market ecosystem [7] - Analysts predict that by 2030, the public fund scale could exceed 50 trillion yuan, driven by deeper financial asset allocation and the entry of long-term capital [7] International Expansion - Leading public funds are increasingly looking to expand internationally, with products like the Southern Dongying CSI A500 ETF being listed on exchanges in Singapore and Hong Kong [8] - Strategic partnerships are being formed, such as the collaboration between Huatai and Korean investment firms to enhance their presence in the Hong Kong ETF market [8]

Group 1 - The Shanghai Municipal Political Consultative Conference held a consultation event focusing on new productive forces, with a particular emphasis on embodied intelligent robots and the establishment of a verification center to avoid redundant investments [1] - The Shanghai Municipal Economic and Information Commission aims to promote the development of low-altitude economy, artificial intelligence industry, and integrated circuit industry, fostering government-enterprise interaction to enhance industrial clusters [1] - Key future industries highlighted in the "14th Five-Year Plan" include quantum technology, biomanufacturing, and brain-computer interfaces, which are areas of active discussion among committee members [1] Group 2 - The number of electric bicycles in Shanghai has reached 12 million, prompting committee members to focus on optimizing road design and improving traffic regulations for this large commuting group [2] - The Shanghai Municipal Transportation Commission is conducting ongoing research to address the changing traffic challenges posed by existing road facilities, with new standards for the construction of the Jiangsu-Yuejiang Tunnel expected to consider the characteristics of electric bicycle usage [2] - The rise of medical tourism has led to the establishment of regulatory standards by the Shanghai Municipal Bureau of Culture and Tourism, in collaboration with 12 departments, to promote the standardized development of the industry [2] Group 3 - A total of 38 government units participated in the consultation event, providing detailed responses to various suggestions from committee members, thereby facilitating communication between government, enterprises, and the public [3]

Core Insights - The central theme of the article emphasizes the importance of cultivating and developing future industries in China, driven by cutting-edge technologies, to seize development opportunities and enhance the modern industrial system [1][2]. Group 1: Importance of Future Industries - Developing future industries is crucial for gaining technological and industrial advantages, improving quality of life, and promoting comprehensive social progress [2]. - By 2025, the industrial and information sectors are expected to contribute over 40% to China's economic growth, with significant advancements in artificial intelligence, quantum technology, and biomanufacturing [2]. Group 2: Strategic Planning and Focus Areas - The focus for the "14th Five-Year Plan" period should be on key areas such as quantum technology, biomanufacturing, hydrogen energy, and brain-computer interfaces, ensuring a strategic approach that considers national needs and technological maturity [3]. - There is a need to prevent disconnection between future industries and traditional sectors, emphasizing the importance of industry integration [3]. Group 3: Role of Technology and Innovation - The pace and depth of future industry development are largely determined by technological breakthroughs, necessitating seamless integration between innovation and industry [4]. - The government is encouraged to leverage a new type of national system to enhance key technology breakthroughs and accelerate the application of scientific achievements [4]. Group 4: Empowering Enterprises - Enterprises are identified as the main drivers of innovation in future industries, requiring a collaborative ecosystem that supports the growth of leading technology firms and specialized small and medium enterprises [5]. - The focus should be on gathering various innovation resources around enterprises to foster continuous advancement in high-end sectors [5]. Group 5: Support and Governance - The government is tasked with providing comprehensive support and establishing a governance framework to facilitate the development of future industries [7]. - This includes improving fiscal policies, promoting technology finance, and ensuring effective talent management while exploring regulatory methods to mitigate risks [7].

Core Insights - The central message emphasizes the importance of cultivating and developing future industries to seize technological and industrial advantages, enhance productivity, and improve the quality of life for citizens [2][3]. Group 1: Future Industry Development - Future industries are characterized by being driven by cutting-edge technologies and are seen as strategic, forward-looking, and disruptive [1]. - Key areas identified for development include quantum technology, biomanufacturing, hydrogen and nuclear fusion energy, brain-computer interfaces, embodied intelligence, and sixth-generation mobile communications [1]. - The contribution of the industrial and information sectors to China's economic growth is projected to exceed 40% by 2025, with over 6,000 AI companies and biomanufacturing evolving into a trillion-dollar industry [2]. Group 2: Strategic Planning and Coordination - A scientific and comprehensive approach is required for planning future industries, focusing on national strategic needs, technological maturity, and resource support [3]. - Emphasis is placed on avoiding a rush into future industries without proper integration with traditional and emerging sectors, promoting continuous industrial convergence [3]. Group 3: Innovation and Technology Integration - The speed and depth of future industry development are significantly influenced by technological breakthroughs, necessitating seamless integration between innovation and industry [4]. - The government is urged to enhance support for key technological advancements and accelerate the application of scientific achievements [4]. Group 4: Role of Enterprises - Enterprises are recognized as the main drivers of innovation, and there is a call to create an ecosystem centered around businesses to foster collaboration and resource aggregation [5]. - The development of leading technology enterprises and support for specialized small and medium-sized enterprises are crucial for advancing industries towards high-end sectors [5]. Group 5: Support and Governance - The cultivation of future industries involves long cycles and significant market risks, requiring government support and a robust governance framework [6]. - Policies related to finance, talent development, and effective regulatory measures are essential to ensure a balance between flexibility and control in the industry [6].

Group 1: Market Overview - The market is currently in a phase of oscillation, with a strong momentum in technology and cyclical sectors, but the short-term market strength is gradually declining [4][5] - Structural characteristics of the market at high valuation levels include increased difficulty in raising sector valuations, stricter conditions for upward breakthroughs, and heightened sensitivity to liquidity shocks [4] - A correction phase is expected before a new upward stage begins in the second half of 2026, driven by improvements in the fundamental cycle and shifts in asset allocation [5] Group 2: Valuation Comparisons - As of January 30, 2026, the valuation metrics for major indices are as follows: - CSI All Share (excluding ST) PE at 22.5x, PB at 1.9x, at historical 83% and 50% percentiles - SSE 50 PE at 11.7x, PB at 1.3x, at historical 61% and 41% percentiles - CSI 300 PE at 14.2x, PB at 1.5x, at historical 65% and 39% percentiles - CSI 500 PE at 37.9x, PB at 2.6x, at historical 70% and 61% percentiles - ChiNext Index PE at 42.6x, PB at 5.7x, at historical 41% and 67% percentiles [7][8] Group 3: Sector Performance - Industries with PE valuations above the 85th percentile historically include real estate, automation equipment, retail, and electronics (semiconductors) [8] - The white goods sector is currently in the bottom 15th percentile for both PE and PB valuations, indicating potential undervaluation [8] Group 4: Global Asset Allocation - The recent hawkish nomination of Kevin Warsh to the Federal Reserve has led to tightening liquidity expectations, causing significant fluctuations in precious metals [10] - The 10-year U.S. Treasury yield rose to 4.26%, and the dollar index is currently at 97.1, reflecting a tightening monetary environment [10] Group 5: Future Industry Trends - Quantum technology is expected to see significant milestones, with predictions of achieving "quantum supremacy" by the end of 2026 [11][12] - The hydrogen energy sector is witnessing rapid development, with major projects being launched and industry chains forming [12]

Quantum Technology - IonQ announced an $1.8 billion acquisition of SkyWater Technology to accelerate its roadmap towards fault-tolerant quantum computing, with plans to start functionality testing of 200,000 qubit QPUs by 2028 [6][8] - A Chinese research team discovered new principles in quantum systems using the 78-qubit superconducting quantum processor "Zhuangzi No. 2," which enhances the application of quantum computing in fields like financial modeling and drug development [7][9] Biomanufacturing - Kangnuo Biopharmaceutical submitted an application for listing on the Hong Kong Stock Exchange, focusing on mitochondrial medicine and NAD+ applications, with projected revenues of 303 million yuan in 2023 [10][11] - Guangdong Province released an action plan aiming for a 40% self-sufficiency rate in core strains of biomanufacturing by 2027, with a total output value exceeding 500 billion yuan [11] Hydrogen Energy and Nuclear Fusion - Sichuan Fusion New Energy Industry Investment Development Co., Ltd. officially commenced operations, supporting the construction of China's first internationally recognized fusion city [13] - CIMC Anrui announced the successful launch of China's first IV-type hydrogen gas bundle container, marking a significant advancement in domestic hydrogen storage and transportation technology [14] - Mingyang Electric and global leaders in hydrogen equipment established Guangdong Mingnuo Hydrogen Technology Co., focusing on high-end hydrogen equipment production [15] Brain-Computer Interface - Neuralink reported 21 participants in its human trials, with plans to enhance device performance by three times and introduce "blindsight" technology for the visually impaired by late 2026 [23][24] - The National Medical Products Administration in China is advancing the establishment of industry standards for brain-computer interface medical devices [28] Embodied Intelligence - Ant Group's Lingbo Technology open-sourced the LingBot-Depth model, significantly lowering development barriers in the industry and enhancing its competitive edge [31][32] 6G and Commercial Aerospace - CASIC successfully conducted a 120 Gbps laser communication experiment, doubling the previous rate and laying the groundwork for high-speed data transmission in commercial aerospace [33][34] - China plans to expand its "Space+" future industries, focusing on space infrastructure, resource development, and space tourism [36] Future Industry Catalysts - Key milestones for future industries in 2026 include significant events in quantum technology, biomanufacturing, hydrogen energy, brain-computer interfaces, embodied intelligence, and 6G [37][38]

医药生物 行 业 研 究 2026 年 02 月 01 日 投资评级：看好（维持） 行业走势图 数据来源：聚源 -10% 0% 10% 19% 29% 38% 2025-02 2025-06 2025-10 医药生物 沪深300 相关研究报告 《原料药行业价格更新—行业周报》 -2026.1.25 《业绩为王，继续重点推荐创新药产 业链板块性机会 — 行 业 周 报 》 -2026.1.18 《减重新靶点初显锋芒，小核酸疗法 前景可期—行业周报》-2026.1.11 供需双改善，国内临床 CRO 行业进入发展新阶段 ——行业周报 | 余汝意（分析师） | 刘艺（联系人） | | --- | --- | | | liuyi1@kysec.cn | | yuruyi@kysec.cn | | | 证书编号：S0790523070002 | 证书编号：S0790124070022 | liuyi1@kysec.cn 证书编号：S0790124070022 中国临床 CRO 行业进入"复苏+稳健增长"新阶段，供需结构持续改善 中国创新药产业已完成从十年前的"离岸外包服务模式"到如今"全球创新资产的 贡献者"的跃迁。临 ...

转自：贵州日报 新年开年的贵州，暖意与新意交织，机遇与实干相拥。 1月27日，省十四届人大四次会议在筑开幕。 也是在这一天，全省电网2026年投资"开门红"标杆工程，贵州500千伏水城（董地）电厂接入系统工程 破土动工。 会场内外，春风携佳讯，发展热潮升腾激荡。 经济持续健康发展，脱贫底线兜牢兜实，产业发展势头强劲，风险管控有力有效，民生保障扎实有 力……回望2025，奋跃而上的贵州，高质量发展迈出新的坚实步伐。 省政府工作报告中，一组组亮眼数据、一个个标志性事件，成为社会各界热议焦点—— "黄小西吃晚饭"等重点景区持续火爆，"村超""村BA"等村字号活动热闹非凡，"支支串飞""小车小团"广 受欢迎； ………… 各区域、各领域的"新"，汇成奋进贵州的新风采。 却顾所来径，苍苍横翠微。 "十四五"时期，在贵州改革发展历程中极不寻常、极不平凡，作为亲历者、见证者和推动者，代表委员 感同身受、意气风发。 "我所工作的旺家社区是万山区最大的易地搬迁安置点，从'搬得出'到'稳得住、能致富'，每一步都充满 不易。"省人大代表、铜仁市万山区丹都街道旺家社区党委书记、居委会主任何英说，看到群众的笑 容，所有艰辛都会化为"走得 ...

Core Viewpoint - Company Kexing Pharmaceutical (科兴制药) is expected to achieve a net profit of approximately 135 million to 175 million yuan in 2025, representing a year-on-year increase of 328.83% to 455.89% compared to the previous year, driven by its "innovation + internationalization" strategy [1] Group 1: Financial Performance - The projected net profit for 2025 is estimated to be between 135 million and 175 million yuan, an increase of 103.52 million to 143.52 million yuan from the previous year [1] Group 2: Strategic Focus - Kexing Pharmaceutical has differentiated its innovation drug pipeline by focusing on three key areas: oncology, autoimmune diseases, and metabolic diseases, which collectively account for 32.2% of the global pharmaceutical market and show significant growth potential [2] - The oncology drug market is expected to grow from 253.3 billion USD in 2024 to 419.8 billion USD by 2030, with a compound annual growth rate of 8.8% [2] Group 3: Product Development - The GB18 injection, targeting GDF-15, is advancing to fill a significant market gap in treating cancer cachexia, with clinical trial approvals from both the FDA and the National Medical Products Administration [2] - Kexing is also developing innovative pipelines for autoimmune diseases, including the GB24 project targeting dual pathways for inflammatory bowel disease and the GB19 project for systemic lupus erythematosus [3] Group 4: AI Integration - In March 2025, Kexing Pharmaceutical entered a strategic partnership with Baidu Biotechnology to leverage AI technology in the development of large molecule drugs for oncology and autoimmune diseases [3] Group 5: International Expansion - Kexing has established a comprehensive global market network covering around 70 countries, with significant sales performance of its core products, including EPOSINO, which leads the market in export volume among similar products [4] - The company has successfully registered and commercialized multiple biopharmaceuticals in Southeast Asia, Latin America, and the Middle East, demonstrating its robust internationalization efforts [4]